Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of bionic reconstituted high-density lipoprotein in preparation of drugs for prevention and treatment of Alzheimer disease

A high-density lipoprotein and Alzheimer's disease technology, applied in the fields of neuropharmacology and chemical pharmacy, can solve problems such as the application of AD prevention and treatment, and achieve the effect of promoting extra-brain transport and reducing inflammatory response in the brain

Inactive Publication Date: 2014-11-12
SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE
View PDF0 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are only sporadic reports on the direct medicinal use of recombinant high-density lipoprotein in the prevention and treatment of atherosclerosis and diabetes, and no research on its application in the prevention and treatment of AD

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of bionic reconstituted high-density lipoprotein in preparation of drugs for prevention and treatment of Alzheimer disease
  • Application of bionic reconstituted high-density lipoprotein in preparation of drugs for prevention and treatment of Alzheimer disease
  • Application of bionic reconstituted high-density lipoprotein in preparation of drugs for prevention and treatment of Alzheimer disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Example 1 Characterization of recombinant high-density lipoprotein

[0030] (1) Preparation

[0031] Lipid (phosphatidylcholine + / - ganglioside + / - cholesterol + / - cholesterol oleate) (2-10 mg) was dissolved in chloroform, and the organic solvent was removed by rotary evaporation under reduced pressure, and the lipid film was added to pH 7.4 Hydrate with phosphate buffer and homogenize with ultrasound at 50°C. Add 0.5-5 mg of ApoE3 and continue to sonicate for 50 min. The product was cooled to room temperature, incubated overnight, and stored at 4°C for later use.

[0032] (2) Characterization

[0033] Recombinant high-density lipoprotein was negatively stained with phosphotungstic acid, and its morphology was observed with a transmission electron microscope. Laser particle size analyzer was used to measure the particle size and surface potential. Analysis of recombinant high-density lipoprotein components: Fluorescence spectrophotometer to measure the amount of en...

Embodiment 2

[0035] Example 2 Recombinant high-density lipoprotein binding Aβ 1-40 monomer, oligomer

[0036] (1) Preparation

[0037] Weigh soy phospholipids, egg phospholipids (2-10 mg) and 0.02 mg fluorescent probe DiI into a round bottom flask, add chloroform to dissolve, place in a rotary evaporator at 20 ° C, and remove the organic solvent under vacuum for 1 h in the dark. Add PBS solution to a round bottom flask, shake at 37°C until the lipid film on the inner wall of the flask is completely hydrated and fall off, ultrasonically reduce the particle size at 40°C, add ApoE or ApoE mimic peptide (0.1-10mg), incubate at 37°C for 36h, 4 Store at ℃.

[0038] (2) Recombinant HDL and Aβ 1-40 In vitro adsorption and binding experiments of monomers and oligomers

[0039] Aβ 1-40 0.05 M pH9.6 sodium carbonate-sodium bicarbonate solution of monomer (concentration: 500 μg / ml) or oligomer (concentration: 500 μg / ml) was added to the plate wells, 50 μl per well, and incubated overnight at 4°C....

Embodiment 3

[0040] Example 3 Aβ-affinity properties of recombinant high-density lipoprotein

[0041] (1) Preparation

[0042] Weigh phosphatidylcholine and phosphatidic acid (2-10 mg) into a round bottom flask, add chloroform to dissolve, and place in a rotary evaporator to remove the organic solvent under reduced pressure. Add PBS solution to the round-bottomed flask, shake at 37°C until the lipid film on the inner wall of the flask is completely hydrated and fall off, homogeneously reduce the particle size at 40°C, add ApoE or ApoA-I (0.1-10mg), incubate at 37°C for 36h, Store at 4°C.

[0043] (2) The surface plasmon resonance (Surface Plasmon Resonance, SPR) experiment verified the Aβ affinity properties of the recombinant HDL.

[0044] The CM5 chip immobilizes Aβ monomers or oligomers by amino coupling: after activating the surface of the chip with 0.2MEDC and 0.05M NHS, dilute Aβ monomers or oligomers in pH4.0 sodium acetate buffer solution In this method, the concentration of Aβ ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Particle sizeaaaaaaaaaa
Particle sizeaaaaaaaaaa
Login to View More

Abstract

Disclosed is a use of bionic recombinant high density lipoprotein (HDL) in the preparation of drugs for preventing and treating Alzheimer's disease. The bionic recombinant HDL consists of lipid and apoprotein. The apoprotein is one or more of ApoE and mimetic peptide thereof, ApoA-I and mimetic peptide thereof, and Apo-II and mimetic peptide thereof, Apoc and mimetic peptide thereof. Preferably, the apoprotein is one or more of ApoE3 and mimetic peptide thereof.

Description

technical field [0001] The invention relates to the fields of neuropharmacology and chemical pharmacy, in particular to the application of bionic recombinant high-density lipoprotein in the preparation of drugs for preventing and treating Alzheimer's disease. Background technique [0002] Alzheimer's Disease (AD) is the most common degenerative disease of the central nervous system that occurs in the elderly population and is characterized by progressive dementia. The clinical manifestations are deteriorating cognitive and memory functions, progressive decline in the ability of daily living, accompanied by various neuropsychiatric symptoms and behavioral disturbances. At present, the incidence of AD in the elderly population is second only to cardiovascular disease, cancer and stroke, and has become the fourth leading cause of death. With the intensification of population aging process, the incidence of such diseases is increasing day by day. According to the "World Alzhei...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/16A61P25/28
CPCA61K9/0019A61K9/0043A61K9/1275A61K38/1709A61P25/28C07K14/775
Inventor 高小玲陈红专宋清香黄萌王小林
Owner SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com